Rhumbline Advisers Vaxcyte, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 164,103 shares of PCVX stock, worth $15.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

164,103

Previous 159,295 3.02%

Holding current value

$15.4 Million

Previous $12 Million 55.76%

% of portfolio

0.02%

Previous 0.01%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$70.52 - $117.12 $339,060 - $563,112	4,808 Added 3.02%	164,103 $18.7 Million
Q2 2024 Aug 01, 2024	BUY	$60.06 - $78.77 $660,720 - $866,548	11,001 Added 7.42%	159,295 $12 Million
Q1 2024 May 09, 2024	BUY	$59.79 - $81.05 $1.06 Million - $1.44 Million	17,743 Added 13.59%	148,294 $10.1 Million
Q4 2023 Feb 08, 2024	BUY	$45.35 - $63.41 $10,929 - $15,281	241 Added 0.18%	130,551 $8.2 Million
Q3 2023 Nov 09, 2023	BUY	$46.0 - $53.1 $282,026 - $325,556	6,131 Added 4.94%	130,310 $6.64 Million
Q2 2023 Aug 08, 2023	BUY	$34.66 - $54.07 $1.01 Million - $1.57 Million	29,005 Added 30.48%	124,179 $6.2 Million
Q1 2023 May 11, 2023	BUY	$36.27 - $47.2 $122,483 - $159,394	3,377 Added 3.68%	95,174 $3.57 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $485,008 - $1.13 Million	23,567 Added 34.54%	91,797 $4.4 Million
Q3 2022 Nov 10, 2022	BUY	$21.69 - $28.53 $144,932 - $190,637	6,682 Added 10.86%	68,230 $1.64 Million
Q2 2022 Aug 11, 2022	BUY	$17.68 - $26.58 $190,219 - $285,974	10,759 Added 21.18%	61,548 $1.34 Million
Q1 2022 May 12, 2022	BUY	$17.46 - $26.36 $67,255 - $101,538	3,852 Added 8.21%	50,789 $1.23 Million
Q4 2021 Feb 10, 2022	SELL	$19.32 - $26.45 $10,355 - $14,177	-536 Reduced 1.13%	46,937 $1.12 Million
Q3 2021 Nov 12, 2021	BUY	$20.26 - $26.97 $43,093 - $57,365	2,127 Added 4.69%	47,473 $1.2 Million
Q2 2021 Aug 05, 2021	BUY	$16.45 - $24.06 $275,751 - $403,317	16,763 Added 58.65%	45,346 $1.02 Million
Q1 2021 May 06, 2021	BUY	$18.66 - $29.16 $115,430 - $180,383	6,186 Added 27.62%	28,583 $565,000
Q4 2020 Feb 10, 2021	BUY	$26.57 - $51.74 $53,033 - $103,273	1,996 Added 9.78%	22,397 $595,000
Q3 2020 Nov 12, 2020	BUY	$26.5 - $55.4 $540,626 - $1.13 Million	20,401 New	20,401 $1.01 Million

Others Institutions Holding PCVX

# of Institutions

354

Shares Held

122M

Call Options Held

775K

Put Options Held

433K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.57B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Vaxcyte, Inc. Transaction History